PPT-ASBM Biosimilars US Prescribers and Biosimilars Naming

Kevin Olson CEO Industry Standard Research KevinOISRreportscom October 2015 Table of contents ASBM US Prescribers and Biosimilars Naming 2 Page 3 Methodology 12 Drug Recording Practices. Day 2. Working backwards: name to formula. It’s. . possible. . to. . determine. . a. . formula. . from. . a. . name. E.g. What is the formula of sodium oxide?. To get the answer, first write the valences:. Paediatric. Prescriptions. A Quality Improvement Project. Dr David Grier, Consultant Paediatrician. Craigavon Area Hospital, Southern Health and Social Care Trust. background. 1 in 5 reported incident on the Paediatric ward in CAH is a medication incident. Project . Naming. / Un visage, un nom. Project . Naming:. is . a community engagement and photographic identification project organized by Library and Archives Canada (LAC) . that began in 2002.. started . Presented by . the Alliance for Safe Bioloigic . Medicines & the Global Colon Cancer Association. . . . . Andrew Spiegel, Esquire. . . andrew.spiegel@globalcca.org. THANK YOU! . Knowledge Connect Slide Resource. This slide deck has been designed to be used as a central resource from which pertinent slides can be extracted as needed . and is not intended for use in its entirety. US Prescribers and Biosimilars Naming. Kevin Olson, CEO. Industry Standard Research. KevinO@ISRreports.com. October, 2015. Table of contents. ASBM - US Prescribers and Biosimilars Naming. 2. Page. 3 . Introduction/Overview . What Is a Biosimilar?. Differences Between Development of Generics and Biosimilar Medications. Clinical Development Program: Biosimilars. Biosimilar Outliers:. "Biomimics" and "Biobetters". OMICS Group Biosimilars 2015 Birmingham, UK. 10-11 Aug 2015. Hazel Gorham . GorhamHazel@prahs.com. Topics. What is a Biosimilar and Why?. Demonstrating Similarity . Quality attributes. Non-clinical animal. C.A.R.E Presentation . February 27, 2015. Ralph Orr. Director, Virginia Prescription Monitoring Program. www.dhp.virginia.gov. Prescription Monitoring Program. 24/7 Database of Schedule II – IV Prescriptions. This program will include a discussion of off-label treatments and investigational agents not approved by the FDA for use in the US, and data that were presented in abstract form. These data should be considered preliminary until published in a peer-reviewed journal.. Alice DOMINIQUE - M2 AREIPS. 1. Content. 2. Definitions. 3. What. . is. a . biological. . medicine. ?. Biological medicine = Biologic medical product . . . . = Biological . . . Key Issues and Challenges.  . Introduction. Differences Between Generics and Biosimilars. Clinical Development Program: . Biosimilars. Differences Between Development of New Generics and New Biosimilar Medications. biosimilars. Prof. dr. Steven Simoens. Health economist. Conflict of interest. I . am one of the founders of the KU Leuven Fund on Market Analysis of Biologics and . Biosimilars. following Loss of Exclusivity (MABEL) . Disclaimer. This panel is moderated by Dr. Delphine Courmier, Executive Director Global Head of Pricing. & Biosimilars Market Access at Organon. The views expressed are those of the speakers and do not necessarily represent the views of ISPOR or Organon..